Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

FDA seeks permanent future for rare pediatric priority review vouchers

 April 9, 2026

Pharmaceutical Technology

The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.

RegulatoryRare DiseaseRead full story

Post navigation

Syneron raises $150m for macrocyclics, and other financings →
← Jeito Capital secures over $1.2bn for new biopharma investments

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com